Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function

Journal of Clinical Investigation

Volumn 106, Issue 10, 2000, Pages 1189-1195

  Khachigian, Levon M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBOCYTIC AGENT; CELL DNA; EARLY GROWTH RESPONSE FACTOR 1; GENE PRODUCT; RIBOZYME; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CATALYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; TRANSCRIPTION REGULATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0033709117     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11620     Document Type: Review

References (50)

1. The pathogenesis of atherosclerosis: A perspective for the 1990s
2. Explosive growth of coronary angioplasty: Success story of a less than perfect procedure
3. Improved coronary outcome after widespread use of coronary-artery stenting in Canada
4. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
5. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
6. Prevention of coronary restenosis
7. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery
8. Egr1-induced endothelial gene expression: A common theme in vascular injury
9. A zinc-finger encoding gene corregulated with c-Fos during growth and differentiation and after depolarization
10. Inducible PDGF A-chain transcription in vascular smooth muscle cells is mediated by Egr-1 displacement of Sp 1 and Sp3
11. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth factor injury
12. Early growth response protein 1 (Egr-1): Prototype of a zinc-finger family of transcription factors
13. Acute local release of fibroblast growth factor-2 bur not transforming growth factor-beta1 following coronary stenting
14. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture
15. Egr-1 induction by injury, is triggered by release and paracrine activation by fibroblast growth factor-2
16. Identification of NAB-1, a repressor of NGFI-A- and Krox20-mediated transcription
17. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli
18. Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury
19. GC factor 2 represses platelet-derived growth factor A-chain transcription and is itself induced by arterial injury
20. High-level expression of Egr-1 and Egr1-inducible genes in mouse and human atherosclerosis
21. Antisense therapy for angioplasty restenosis: Some critical considerations
22. Controversies in the cellular pharmacology of oligodeoxynucleotides
23. Frontiers in interventional cardiology
24. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty
25. Antisense oligonucleotoide against c-myc administered with the Transport delivery catheter for the prevention of in-stent restenosis: Results of the randomized ITALICS trial
26. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequencing of retrahymena
27. Nuclease-resisrant synthetic ribozymes: Developing a new class of therapeutics
28. Self-cleaving catalytic RNA
29. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo
30. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model
31. Escort aptamers: A delivery service for diagnosis and therapy
32. Developing aptamers into therapeutics
33. DNA enzymes
34. A general purpose RNA-cleaving DNA enzyme
35. Nucleic acid mutation analysis using catalytic DNA
36. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA
37. Mechanism and utility of an RNA-cleaving DNA enzyme
38. Sequence-specific cleavage of the HIV1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: Inhibition of the coreceptor function by DNA-enzyme
39. Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated celt fusion
40. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme
41. Chemical modification of hammerhead ribozymes
42. Design of nuclease resistant protein kinase C-alpha DNA enzymes with potential therapeutic application
43. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme
44. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA
45. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome
46. Inhibition of bcr-abl oncogene by novel deoxyribozymes (DNAzymes)
47. DzyNA-PCR: Use of DNAzymes to detect and quantify nucleic acid sequences in a real-time fluorescent format
48. UV irradiation upregulates Egr-1 expression at transcription level
49. Vascular smooth muscle cell proliferation and regrowrh after injury in vitro is dependent upon NGFI-A/Egr-1
50. Histopathology of in-stent restenosis in patients with peripheral artery disease